Q-omics provides the consensus-scored RPS10P9 profile across patient tissues and cancer cell-line models. RPS10P9 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RPS10P9 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, RPS10P9 RNA expression shows 16,200 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight CESC, KIRC, and DLBC as cancer lineages where RPS10P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS10P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS10P9 survival associations across molecular data types. RPS10P9 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS10P9 RNA expression–survival associations across cancer types. High RPS10P9 expression shows unfavorable associations in LIHC, SARC, UCEC and ACC, but favorable associations in CESC and BLCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RPS10P9 RNA expression.
This table summarizes RPS10P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS10P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS10P9 shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, CHOL, LUAD and LUSC. The KIRC box plot shows higher RPS10P9 RNA expression in tumor versus normal tissue (log2 FC = +0.495, t-test p < 0.001).
This table shows molecular features associated with RPS10P9 in patient tissues and cancer cell lines. In patient samples, RPS10P9 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
